Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Citigroup

Citigroup upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a neutral rating to a buy rating in a research note published on Wednesday morning, MarketBeat Ratings reports. The firm currently has $700.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $600.00.

Several other brokerages have also issued reports on REGN. Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Bernstein Bank reduced their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. The Goldman Sachs Group reduced their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a research note on Wednesday, April 30th. Finally, Royal Bank of Canada reduced their price objective on shares of Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $890.60.

Regeneron Pharmaceuticals Trading Up 1.6%

Shares of Regeneron Pharmaceuticals stock opened at $594.32 on Wednesday. The stock has a market capitalization of $64.17 billion, a P/E ratio of 15.53, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a 50-day simple moving average of $599.96 and a 200 day simple moving average of $684.64. Regeneron Pharmaceuticals has a 12-month low of $520.50 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter last year, the business earned $9.55 EPS. Research analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a $0.88 dividend. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.59%. Regeneron Pharmaceuticals’s payout ratio is presently 8.96%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of REGN. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 31 shares during the last quarter. Activest Wealth Management lifted its holdings in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the last quarter. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $27,000. Finally, Saudi Central Bank acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.